Refractory Cancer Clinical Trial
Official title:
A Pilot Study Utilizing Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
This is an open-label, multicenter pilot study in patients with advanced solid tumors.
The primary objective of this study is to compare progression-free survival using a
treatment regimen selected by molecular profiling with progression-free survival for the
most recent regimen the patient has progressed on.
To be eligible, patients must have received at least two lines of prior chemotherapeutic,
hormonal or biological regimens for advanced disease, have measurable or evaluable,
refractory disease and have clear documentation of the time between treatment start and
documented progression on the last treatment prior to study entry. Eligible patients must
undergo or have available a tumor biopsy for molecular profiling within 2 months of IHC/FISH
and/or DNA microarray analysis.
n/a
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03336931 -
PRecISion Medicine for Children With Cancer
|
||
| Recruiting |
NCT05852717 -
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT06229340 -
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
|
Phase 2 | |
| Completed |
NCT00551850 -
A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients
|
Phase 1 | |
| Recruiting |
NCT06104488 -
A Study of Avutometinib for People With Solid Tumor Cancers
|
Phase 1 | |
| Terminated |
NCT04092179 -
Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06184035 -
A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06024603 -
Individualized Treatments in Adults With Relapsed/Refractory Cancers
|
N/A | |
| Recruiting |
NCT05859074 -
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
|
Phase 1 | |
| Recruiting |
NCT05864144 -
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03187288 -
Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS
|
Phase 1 | |
| Terminated |
NCT01320280 -
BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer
|
Phase 2 | |
| Completed |
NCT03441100 -
TCR-engineered T Cells in Solid Tumors: IMA202-101
|
Phase 1 | |
| Recruiting |
NCT05359445 -
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03686124 -
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04337580 -
Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04310345 -
Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents
|
N/A | |
| Recruiting |
NCT05669430 -
A Study of GV20-0251 in Patients With Solid Tumor Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT06208657 -
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05662397 -
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
|
Phase 1/Phase 2 |